#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to understand that young adults often lack accurate knowledge about cannabis risks, which may lead to underestimation of potential harms when patients self-report use or decline to disclose it. This knowledge gap directly impacts clinical assessment and counseling effectiveness, requiring providers to proactively educate patients about documented risks rather than assuming awareness. Addressing misconceptions during routine care can improve shared decision-making and help patients make informed choices about cannabis use.
A recent study examining cannabis risk awareness in young adults reveals substantial knowledge gaps about the health consequences of cannabis use, particularly regarding potential effects on cognitive development, mental health, and driving safety. Young adults demonstrate limited understanding of dose-dependent risks and the distinction between occasional and chronic use patterns, with many underestimating the potency of modern cannabis products, especially high-THC concentrates. These findings are clinically significant because inadequate risk perception among younger populations may contribute to delayed help-seeking behavior, underreporting of cannabis-related symptoms during clinical encounters, and reduced motivation for harm reduction strategies. Clinicians caring for adolescents and young adults should recognize this knowledge gap as a barrier to informed decision-making and view patient education about cannabis risks as a core preventive health intervention. For practitioners, routine assessment of cannabis use should be paired with structured counseling about specific health risks relevant to age, frequency of use, and product type to bridge this critical information gap and support evidence-based decision-making among young patients.
“What we’re seeing in clinical practice mirrors this research exactly: young adults have absorbed the message that cannabis is safer than alcohol without understanding that safety is dose, frequency, and individual neurobiology dependent, and that’s creating a real problem for those with emerging psychosis risk or developing brains. Until we integrate honest cannabis education into primary care and public health, we’ll continue managing preventable psychiatric complications that could have been identified or avoided with basic risk stratification upfront.”
🧠 This study identifying knowledge gaps about cannabis risks among young adults underscores a critical clinical education challenge, as patients may seek cannabis for symptom management without understanding potential harms including cognitive impairment, dependence, or drug interactions. Healthcare providers should recognize that limited public awareness about cannabis risks does not reflect the actual evidence base, which documents real concerns particularly for developing brains and vulnerable populations, though the magnitude of individual risk varies considerably based on age, frequency of use, product potency, and route of administration. The gap between public perception and clinical evidence is further complicated by evolving regulatory landscapes and inconsistent medical messaging across jurisdictions, which can undermine patient trust and shared decision-making. When counseling patients about cannabis use, clinicians should provide evidence-based risk information tailored to individual circumstances, assess baseline cognitive and mental health status, and remain alert to signs of problematic use patterns, while acknowledging genuine therapeutic interest and maintaining non-judgmental
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
